June 13, 2017 / 12:30 PM / a month ago

BRIEF-Pfizer and Lilly receive FDA fast track designation for Tanezumab

1 Min Read

June 13 (Reuters) - Pfizer Inc:

* Pfizer and Lilly receive FDA fast track designation for Tanezumab

* ‍phase 3 global clinical development program for Tanezumab is currently ongoing​

* ‍Results are projected to begin reporting out in 2018​ Source text for Eikon: Further company coverage: and

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below